US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

AbbVie (NY:ABBV)

265.76 +2.94 (+1.12%)
Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
3 Dividend Stocks That Are Screaming Buys in November ↗
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
News headline image
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback ↗
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
News headline image
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in AbbVie ↗
 
Via Benzinga
News headline image
What To Do After The Worst Week For Healthcare Stocks Since March 2020? ↗
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
News headline image
Where Will AbbVie Be in 5 Years? ↗
Via The Motley Fool
News headline image
Smart Money Is Betting Big In ABBV Options ↗
 
Via Benzinga
News headline image
Seeking Beta ↗
While the “Trump rally” appears to have just begun, one of its initial hallmarks is that investors want beta. 
Via Talk Markets
News headline image
Navigating 14 Analyst Ratings For AbbVie ↗
 
Via Benzinga
News headline image
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip ↗
Via The Motley Fool
News headline image
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers ↗
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga
News headline image
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' ↗
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. 
Via Benzinga
News headline image
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock ↗
The drugmaker has convincingly laid to rest the biggest threat to its top line. 
Via The Motley Fool
News headline image
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy? ↗
With the loss of Humira’s exclusivity and a recent dip in stock value, many are questioning the future trajectory of AbbVie stock. 
Via Talk Markets
News headline image
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip? ↗
AbbVie reports disappointing mid-stage data for its schizophrenia drug. 
Via Talk Markets
News headline image
This Is What Whales Are Betting On AbbVie ↗
 
Via Benzinga
News headline image
My Favorite Dividend King to Buy in November ↗
This Dividend King truly wears the crown. 
Via The Motley Fool
News headline image
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom ↗
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3. 
Via Benzinga
News headline image
2 Dividend Stocks to Buy Hand Over Fist in November ↗
These companies have solid businesses and excellent dividend growth track records. 
Via The Motley Fool
News headline image
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
News headline image
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock ↗
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
News headline image
Biotech Stocks Are Rallying: What Is Your Playbook? ↗
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why AbbVie Stock Was Getting Mashed on Monday ↗
A splashy recent acquisition by the company might not be panning out. 
Via The Motley Fool
News headline image
What's Going On With Bristol-Myers Squibb Shares Monday? ↗
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet... 
Via Benzinga
News headline image
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated ↗
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline. 
Via Benzinga
News headline image
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges ↗
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps. 
Via Benzinga
News headline image
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails ↗
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies. 
Via Investor's Business Daily
News headline image
3 Spectacular High-Yield Dividend Stocks to Buy in November ↗
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >